The paper, 'Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women: a randomized controlled trial', by Hackman et al.,
1 is difficult to interpret for a number of reasons. The title of the paper, introductory statements and conclusions all suggest that the study is controlled for the inclusion of ephedra and caffeine. However, examination of the many differences between the control and treatment supplements ( , using a product that provided 1200 mg/day of HCA in a randomized, double-blind design (approximating the dose in the Hackman study), demonstrated increased weight loss in overweight female human subjects. Weight loss over the 12-week study was 3.773.1 kg in the treatment group and 2.472.9 kg for placebo subjects; the difference of 1.3 kg was statistically significant (P ¼ 0.026). The difference in weight loss between treated and control patients in the Hackman study for the first 12 weeks averaged 2.1 kg; thus, HCA could have accounted for approximately 60% of that weight loss.
Another potential weakness in the paper is that the treatment group had a significantly greater average baseline body weight than the placebo group (by 4.3 kg; Po0.05), and a greater average baseline caloric intake (1930 kcal for treated and 1580 kcal for controls; P ¼ 0.005). The importance of baseline weight and intake in relation to body weight loss is obvious.
A final concern relates to the assessment of untoward events by the authors. Palpitations are described as a 'minor symptom'. Palpitations may represent a prelude to a serious ischemic event. The American College of Physicians 3 and family practice perspectives 4 provide similar diagnostic algorithms for 'palpitations', which require a patient history, physical examination and a 12-lead electrocardiogram. It is noteworthy that the Hackman study demonstrated a highly significant increased incidence of palpitations in the treated group (Table 6 ). Thirteen subjects (of 29 that started and 19 that finished) reported palpitations, whereas, only one control subject reported palpitations. In view of the small weight loss in this study that may be attributable to ephedra alkaloids and caffeine, and the potential for attending cardiovascular risks, it would appear difficult to conclude that this prescription represents a useful option for the treatment of obesity.
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